HistoSonics® Completes First Patient Enrollment in the Company’s Innovative BOOMBOX Primary Study
Tuesday, November 19, 2024
HistoSonics, developer and manufacturer of the Edison® tissue ablation system, today announced the enrolment of the first patients in its innovative prospective master study, BOOMBOX, designed to evaluate the real-world use of tissue ablation in the treatment of liver tumors. BOOMBOX is a comprehensive, post-marketing master study that will provide important data on up to 5,000 patients treated by a growing number of multidisciplinary tissue ablation providers worldwide. The master study design is unique in the medical device industry as it captures data on the treatment of patients with a variety of tumor types and disease stages. These patients have a variety of interventional needs and span multiple clinical specialties.
“In the past, addressing this complexity has required multiple separate study protocols over an extended period of time, delaying access to tissue destruction for patients in need,” said Amanda Cafaro, Vice President of Clinical Affairs at HistoSonics. “ We designed this post-marketing master study and its accompanying sub-studies to deepen our understanding of a variety of clinically relevant research questions to accelerate access to this innovative therapy.”
The primary endpoint of the BOOMBOX study will evaluate the ability of tissue ablation to be a versatile tool, and subsequent sub-studies will evaluate additional endpoints to demonstrate increasingly specific therapeutic applications: as a monotherapy, in combination, as a curative treatment, and as a foundation for other treatments. Several tissue ablation clinical treatment centers in the United States have already started recruiting for the BOOMBOX study, and the company hopes that tissue ablation research institutions in the United States and around the world will participate.
“ Tissue ablation offers my patients with liver tumors a completely new treatment option with a clinically demonstrated significant risk-benefit advantage,” said Juan P. Rocca, MD, MHA, surgical director of the Liver Cancer Program at NewYork-Presbyterian Hospital and Weill Cornell Medicine, one of the centers offering tissue ablation in the United States. “By participating in the BOOMBOX study, we are participating in practical, real-world research that will advance this innovative platform and explore new ways to use tissue ablation in the future.”
“As part of the BOOMBOX study, we will collect broad and deep data that will provide us and our tissue ablation program partners with insights into how tissue ablation impacts a variety of diseases and patient conditions,” said Joe Herman, MD, vice president of medical affairs at HistoSonics. “BOOMBOX is our long-term commitment to understanding how tissue ablation can best improve the lives of patients with liver tumors and the debilitating symptoms these patients face.”
The BOOMBOX study kicks off HistoSonics' post-marketing evidence generation work in the liver field. Previously, as part of HistoSonics' market access application, the company submitted data from the recently announced pivotal clinical trial #HOPE4LIVER to the U.S. Food and Drug Administration (FDA), and received De Novo approval from the FDA in October 2023, allowing tissue ablation to be used for non-invasive destruction of liver tumors. In addition to the BOOMBOX: Main Study, HistoSonics has also established an ongoing investigator-sponsored research program aimed at supporting tissue ablation providers to conduct independent research through grants to promote the safe and effective use of tissue ablation.
The Edison System is intended for noninvasive mechanical destruction of liver tumors, including partial or complete destruction of unresectable liver tumors by tissue destruction. The FDA has not evaluated the Edison System for the treatment of any disease, including but not limited to cancer, nor has it evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival, or overall survival). The system should only be used by physicians who have completed HistoSonics training, and its use should be guided by the clinical judgment of an appropriately trained physician. For a complete list of warnings, precautions, and a summary of clinical trial results, including reported adverse events, please refer to the device Instructions for Use.
HistoSonics Company Overview
HistoSonics is a privately held medical device company developing a non-invasive platform and proprietary acoustic beam therapy using tissue ablation, a novel mechanism of action that uses focused ultrasound to mechanically destroy and liquefy unwanted tissue and tumors. The company is currently focused on commercializing its Edison System for liver treatments in the U.S. and select global markets, while expanding the use of tissue ablation to other organs such as the kidney and pancreas. HistoSonics has offices in Ann Arbor, Michigan, and Minneapolis, Minnesota.
For more information about the BOMBOX study, please search for the study on ClinicalTrials.gov using reference number NCT06486454 . For information about the Edison Tissue Destruction System, please visit: www.histosonics.com/ . For patient information, please visit: www.myhistotripsy.com/ .
Disclaimer: The original version of this announcement is the official authorized version. The translation is for convenience only. Please refer to the original text, which is the only version with legal effect.
Contacts
Media Contact:
Josh King
Vice President, Global Market Access
Joshua.king@histosonics.com
608-332-8124
Kimberly Ha
KKH Advisors
kimberly.ha@kkhadvisors.com
917-291-5744
Source: businesswire.com